124 related articles for article (PubMed ID: 16682186)
1. Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621.
Huang S; Connolly PJ; Lin R; Emanuel S; Middleton SA
Bioorg Med Chem Lett; 2006 Jul; 16(14):3639-41. PubMed ID: 16682186
[TBL] [Abstract][Full Text] [Related]
2. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
Emanuel S; Rugg CA; Gruninger RH; Lin R; Fuentes-Pesquera A; Connolly PJ; Wetter SK; Hollister B; Kruger WW; Napier C; Jolliffe L; Middleton SA
Cancer Res; 2005 Oct; 65(19):9038-46. PubMed ID: 16204078
[TBL] [Abstract][Full Text] [Related]
3. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.
Lin R; Connolly PJ; Huang S; Wetter SK; Lu Y; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Rugg CA; Middleton SA; Jolliffe LK
J Med Chem; 2005 Jun; 48(13):4208-11. PubMed ID: 15974571
[TBL] [Abstract][Full Text] [Related]
4. O-N intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence-containing bioactive peptides.
Sohma Y; Hayashi Y; Skwarczynski M; Hamada Y; Sasaki M; Kimura T; Kiso Y
Biopolymers; 2004; 76(4):344-56. PubMed ID: 15386265
[TBL] [Abstract][Full Text] [Related]
5. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Griffin RJ; Henderson A; Curtin NJ; Echalier A; Endicott JA; Hardcastle IR; Newell DR; Noble ME; Wang LZ; Golding BT
J Am Chem Soc; 2006 May; 128(18):6012-3. PubMed ID: 16669651
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates.
Wong C; Griffin RJ; Hardcastle IR; Northen JS; Wang LZ; Golding BT
Org Biomol Chem; 2010 May; 8(10):2457-64. PubMed ID: 20448906
[TBL] [Abstract][Full Text] [Related]
7. New water-soluble sulfonylphosphoramidic acid derivatives of the COX-2 selective inhibitor cimicoxib. A novel approach to sulfonamide prodrugs.
Almansa C; Bartrolí J; Belloc J; Cavalcanti FL; Ferrando R; Gómez LA; Ramis I; Carceller E; Merlos M; García-Rafanell J
J Med Chem; 2004 Oct; 47(22):5579-82. PubMed ID: 15481993
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption.
Okaniwa M; Imada T; Ohashi T; Miyazaki T; Arita T; Yabuki M; Sumita A; Tsutsumi S; Higashikawa K; Takagi T; Kawamoto T; Inui Y; Yoshida S; Ishikawa T
Bioorg Med Chem; 2012 Aug; 20(15):4680-92. PubMed ID: 22763369
[TBL] [Abstract][Full Text] [Related]
9. Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration.
Singh SK; Vobbalareddy S; Kalleda SR; Casturi SR; Datla SR; Mamidi RN; Mullangi R; Ramanujam R; Yeleswarapu KR; Iqbal J
Bioorg Med Chem; 2006 Dec; 14(24):8626-34. PubMed ID: 16949828
[TBL] [Abstract][Full Text] [Related]
10. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
[TBL] [Abstract][Full Text] [Related]
11. N-acylated sulfonamide sodium salt: a prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors.
Singh SK; Vobbalareddy S; Kalleda SR; Casturi SR; Mullangi R; Ramanujam R; Yeleswarapu KR; Iqbal J
Bioorg Med Chem Lett; 2006 Aug; 16(15):3921-6. PubMed ID: 16730986
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of new dipyrrolo- and furopyrrolopyrazinones related to tripentones and their biological evaluation as potential kinases (CDKs1-5, GSK-3) inhibitors.
Rochais C; Duc NV; Lescot E; Sopkova-de Oliveira Santos J; Bureau R; Meijer L; Dallemagne P; Rault S
Eur J Med Chem; 2009 Feb; 44(2):708-16. PubMed ID: 18586356
[TBL] [Abstract][Full Text] [Related]
13. Concise synthesis and CDK/GSK inhibitory activity of the missing 9-azapaullones.
Power DP; Lozach O; Meijer L; Grayson DH; Connon SJ
Bioorg Med Chem Lett; 2010 Aug; 20(16):4940-4. PubMed ID: 20621478
[TBL] [Abstract][Full Text] [Related]
14. Poly(ethylene glycol) prodrugs of the CDK inhibitor, alsterpaullone (NSC 705701): synthesis and pharmacokinetic studies.
Greenwald RB; Zhao H; Xia J; Wu D; Nervi S; Stinson SF; Majerova E; Bramhall C; Zaharevitz DW
Bioconjug Chem; 2004; 15(5):1076-83. PubMed ID: 15366962
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
16. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
Chao Q; Sprankle KG; Grotzfeld RM; Lai AG; Carter TA; Velasco AM; Gunawardane RN; Cramer MD; Gardner MF; James J; Zarrinkar PP; Patel HK; Bhagwat SS
J Med Chem; 2009 Dec; 52(23):7808-16. PubMed ID: 19754199
[TBL] [Abstract][Full Text] [Related]
17. Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa.
Maryanoff BE; McComsey DF; Costanzo MJ; Yabut SC; Lu T; Player MR; Giardino EC; Damiano BP
Chem Biol Drug Des; 2006 Jul; 68(1):29-36. PubMed ID: 16923023
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38α inhibitor.
Liu C; Lin J; Everlof G; Gesenberg C; Zhang H; Marathe PH; Malley M; Galella MA; McKinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2013 May; 23(10):3028-33. PubMed ID: 23578688
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2.
Najda-Bernatowicz A; Łebska M; Orzeszko A; Kopańska K; Krzywińska E; Muszyńska G; Bretner M
Bioorg Med Chem; 2009 Feb; 17(4):1573-8. PubMed ID: 19168362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
